Tradestie Institutional Equity Comparison Engine
BU vs MBX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MBX Overall Edge
MBX Captures Institutional Edge (3โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MBX Biosciences, Inc. Common Stock (MBX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BU trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus MBX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, BU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MBX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BU N/M vs MBX N/M Fwd P/E
Growth & Margin Winner
MBX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
MBX
1Y -9.1% vs +120.7% ยท 52W Pos 6% vs 61%
Options & Structure Winner
MBX
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (<1st %ile IV)
BU
US Equity
BU
Institutional Equity
$18.17
+0.46% 1D
Market Cap
N/A
1M Return
-14.04%
1Y Return
-9.12%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 40.0
Fund 46.0
Flow 50.0
Mom 48.2
MBX
NASDAQ
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.12
-5.04% 1D
Market Cap
$2.8B
1M Return
+7.08%
1Y Return
+120.69%
Forward P/E
N/M
Unified AI Score
45.1 / 100
HOLD
Tech 42.0
Fund 48.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BU -9.12%
MBX +120.69%
Spread: +15.0 pp (MBX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BU TTM Op. Margin: N/A
MBX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BU vs MBX. Trailing 12-month operating profitability (BU N/A vs MBX 0.0%) and valuation multiples (BU N/M vs MBX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BU | MBX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $2.8B | Larger Scale | MBX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | MBX |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | MBX |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | MBX |
| Return on Equity (ROE) Capital Efficiency | N/A | -33.7% | Higher ROE | MBX |
| 52-Week Range Position Momentum | 6% ($17โ$39) | 61% ($23โ$73) | Stronger Trend | MBX |
| Beta / 30D Volatility Risk Regime | 3.91ฮฒ ยท 97% Vol | 1.58ฮฒ ยท 66% Vol | Lower Realized Risk | MBX |
| Unified Institutional Score Composite Signal | 53.5 / 100 (HOLD) | 45.1 / 100 (HOLD) | Higher Composite | BU |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BU vs MBX Buy Guide
BU
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
MBX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BU nor MBX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.